GALECTIN THERAPEUTICS INC
GALT · XNASCIK 1133416fmd_04F94NZF4AP75Q08CTAJS0QFGAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2010 to Jun 30, 2026, 65 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 15 | 12 | 6 | 7 | 18 | 24 | 32 | 32 | 37 | 14 |
| Total operating expenses | 21 | 16 | 14 | 13 | 23 | 30 | 38 | 38 | 42 | 20 |
| Operating income | (21) | (16) | (14) | (13) | (23) | (30) | (38) | (38) | (42) | (20) |
| Interest expense | – | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 6 | 7 |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | 0 | (0) | 0 | (0) | (0) | (0) | (3) | (5) | (11) |
| Income tax expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Net income | (21) | (16) | (14) | (13) | (23) | (31) | (39) | (41) | (47) | (31) |
| Net income to common shareholders | (22) | (17) | (15) | (20) | (24) | (31) | (39) | (45) | (47) | (31) |